Back to search results
Active, not recruiting

Advanced Cancer

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

JTJF | {{ defaultRegistry.registryAnchorText }} NCT02124148 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.

Time Commitment

Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18+ years
  • Participant in Part A, C, D or E must have diagnosis of cancer that is advanced or metastatic
  • Participant in Part B must have confirmed Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colorectal cancer that is metastatic or recurrent and has failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant of irinotecan or oxaliplatin
  • Participant must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy
  • Participant must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment
  • Participant must have completed radiation therapy and surgery at least 4 weeks before study enrollment
  • Participant of reproductive potential must agree to use medically approved contraceptive precautions during the study and for six months (Parts A and B) or for three months (Parts C, D, and E) following the last dose of study drug
  • Female participant of childbearing potential must have had a negative pregnancy test within 14 days of the first dose of study drug and must not be breast feeding
  • Participant must not have an active fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
  • Participant must not have acute leukemia or a serious heart condition such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months
  • Part E Participant must not have insulin-dependent (type I) diabetes, a history of gestational diabetes, prior treatment with a PI3K/mTOR inhibitor and must be able to swallow capsules or tablets

Where to Participate

Where to Participate

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.